Free Trial
NASDAQ:XLO

Xilio Therapeutics (XLO) Stock Price, News & Analysis

Xilio Therapeutics logo
$0.75 0.00 (-0.64%)
Closing price 04:00 PM Eastern
Extended Trading
$0.76 +0.01 (+0.77%)
As of 04:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Xilio Therapeutics Stock (NASDAQ:XLO)

Key Stats

Today's Range
$0.75
$0.78
50-Day Range
$0.65
$0.98
52-Week Range
$0.62
$1.70
Volume
56,137 shs
Average Volume
1.17 million shs
Market Capitalization
$38.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00
Consensus Rating
Buy

Company Overview

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Xilio Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
71st Percentile Overall Score

XLO MarketRank™: 

Xilio Therapeutics scored higher than 71% of companies evaluated by MarketBeat, and ranked 391st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Xilio Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Xilio Therapeutics has received no research coverage in the past 90 days.

  • Read more about Xilio Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Xilio Therapeutics are expected to grow in the coming year, from ($1.14) to ($0.40) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Xilio Therapeutics is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Xilio Therapeutics is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Xilio Therapeutics has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Xilio Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    3.55% of the float of Xilio Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Xilio Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Xilio Therapeutics has recently decreased by 12.75%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Xilio Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Xilio Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.55% of the float of Xilio Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Xilio Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Xilio Therapeutics has recently decreased by 12.75%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Xilio Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Xilio Therapeutics this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    5 people have added Xilio Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Xilio Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.20% of the stock of Xilio Therapeutics is held by insiders.

  • Percentage Held by Institutions

    54.29% of the stock of Xilio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Xilio Therapeutics' insider trading history.
Receive XLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

XLO Stock News Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
Xilio Therapeutics reports Q4 EPS (20c) vs (64c) last year
Xilio Therapeutics files $250M mixed securities shelf
See More Headlines

XLO Stock Analysis - Frequently Asked Questions

Xilio Therapeutics' stock was trading at $0.9550 at the beginning of 2025. Since then, XLO stock has decreased by 21.4% and is now trading at $0.7502.
View the best growth stocks for 2025 here
.

Xilio Therapeutics, Inc. (NASDAQ:XLO) issued its quarterly earnings results on Tuesday, March, 11th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.02. The firm earned $1.72 million during the quarter, compared to analyst estimates of $2.26 million.

Xilio Therapeutics (XLO) raised $125 million in an initial public offering on Friday, October 22nd 2021. The company issued 7,353,000 shares at $16.00-$18.00 per share.

Xilio Therapeutics' top institutional shareholders include Avantax Planning Partners Inc. (0.29%). Insiders that own company stock include Gilead Sciences, Inc, Venture Fund Xi LP Atlas, Christopher James Frankenfield and Kevin M Brennan.
View institutional ownership trends
.

Shares of XLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Xilio Therapeutics investors own include PayPal (PYPL), Achilles Therapeutics (ACHL), JPMorgan Chase & Co. (JPM), AT&T (T), United Microelectronics (UMC), Adverum Biotechnologies (ADVM) and Atai Life Sciences (ATAI).

Company Calendar

Last Earnings
3/11/2025
Today
5/02/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:XLO
Fax
N/A
Employees
70
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$4.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+429.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-76,400,000.00
Pretax Margin
-1,359.37%

Debt

Sales & Book Value

Annual Sales
$6.34 million
Price / Cash Flow
N/A
Book Value
$1.34 per share
Price / Book
0.56

Miscellaneous

Free Float
41,672,000
Market Cap
$39.09 million
Optionable
Not Optionable
Beta
-0.25
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:XLO) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners